Frontiers in Microbiology,
Journal Year:
2022,
Volume and Issue:
13
Published: Aug. 8, 2022
Antimicrobial
and
anticancer
drug
resistance
represent
two
of
the
main
global
challenges
for
public
health,
requiring
immediate
practical
solutions.
In
line
with
this,
we
need
a
better
understanding
origins
in
prokaryotic
eukaryotic
cells
evolutionary
processes
leading
to
occurrence
adaptive
phenotypes
response
selective
pressure
therapeutic
agents.
The
purpose
this
paper
is
present
some
analogies
between
antimicrobial
resistance.
drugs
share
common
targets
mechanisms
action
as
well
similar
(e.g.,
increased
efflux,
inactivation,
target
alteration,
persister
cells’
selection,
protection
bacterial
communities/malignant
tissue
by
an
extracellular
matrix,
etc.).
Both
individual
collective
stress
responses
triggered
chemotherapeutic
agent
involving
complex
intercellular
communication
processes,
surrounding
microenvironment,
will
be
considered.
themes
recommend
utility
experimental
models
unraveling
that
facilitate
evolution
adaptation
malignant
antineoplastic
drugs.
Microorganisms,
Journal Year:
2022,
Volume and Issue:
11(1), P. 107 - 107
Published: Dec. 31, 2022
Pre-clinical
models
and
clinical
studies
highlight
the
significant
impact
of
host–microbiota
relationship
on
cancer
development
treatment,
supporting
emerging
trend
for
a
microbiota-based
approach
in
oncology.
Importantly,
presence
polymorphic
microbes
is
considered
one
hallmarks
cancer.
The
epigenetic
regulation
gene
expression
by
microRNAs
affects
crucial
biological
processes,
including
proliferation,
differentiation,
metabolism,
cell
death.
Recent
evidence
has
documented
existence
bidirectional
gut
microbiota–microRNA
interactions
that
play
critical
role
intestinal
homeostasis.
alterations
microRNA-modulated
are
known
to
be
associated
with
inflammatory
responses
dysbiosis
gastrointestinal
disorders.
In
this
review,
we
summarize
current
findings
about
miRNA
intestine
focus
specific
microbiota–miRNA
linked
homeostasis,
immune
system,
development.
We
discuss
potential
utility
fecal
profiling
as
diagnostic
prognostic
tool
colorectal
cancer,
demonstrate
how
microbiota
modulation,
together
use
personalized
microRNA
therapeutics,
might
bring
improvements
outcomes
patients
era
precision
medicine.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(24), P. 17199 - 17199
Published: Dec. 6, 2023
Cancer
cell
dissemination
involves
invasion,
migration,
resistance
to
stressors
in
the
circulation,
extravasation,
colonization,
and
other
functions
responsible
for
macroscopic
metastases.
By
enhancing
invasiveness,
motility,
intravasation,
epithelial-to-mesenchymal
transition
(EMT)
process
promotes
generation
of
circulating
tumor
cells
their
collective
migration.
Preclinical
clinical
studies
have
documented
intensive
crosstalk
between
gut
microbiome,
host
organism,
immune
system.
According
findings,
polymorphic
microbes
might
play
diverse
roles
tumorigenesis,
cancer
progression,
therapy
response.
Microbial
imbalances
changes
levels
bacterial
metabolites
toxins
promote
progression
via
EMT
angiogenesis.
In
contrast,
a
favorable
microbial
composition,
together
with
microbiota-derived
metabolites,
such
as
short-chain
fatty
acids
(SCFAs),
can
attenuate
processes
initiation,
disease
formation
distant
this
review,
we
highlight
role
intratumoral
microbiomes
metastatic
ability
outline
potential
options
microbiota
modulation.
As
shown
murine
models,
probiotics
inhibited
development,
reduced
volume,
suppressed
angiogenesis
metastasis.
Moreover,
modulation
an
unfavorable
microbiome
improve
efficacy
reduce
treatment-related
toxicities,
bringing
benefit
patients
cancer.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(14), P. 11855 - 11855
Published: July 24, 2023
Over
the
years,
cancer
has
been
affecting
lives
of
many
people
globally
and
it
become
one
most
studied
diseases.
Despite
efforts
to
understand
cell
mechanisms
behind
this
complex
disease,
not
every
patient
seems
respond
targeted
therapies
or
immunotherapies.
Drug
resistance
in
is
limiting
factors
contributing
unsuccessful
therapies;
therefore,
understanding
how
cells
acquire
essential
help
cure
individuals
affected
by
cancer.
Recently,
altered
microbiome
was
observed
be
an
important
hallmark
therefore
represents
a
promising
topic
research.
Our
review
aims
provide
global
perspective
some
hallmarks,
for
instance
genetic
epigenetic
modifications
may
caused
human
microbiome.
We
also
information
on
can
lead
development
as
well
influence
drug
ultimately
therapies.
This
useful
develop
alternatives
treatment,
i.e.,
future
personalized
medicine
that
cases
where
traditional
treatment
unsuccessful.
Pathogens,
Journal Year:
2023,
Volume and Issue:
12(6), P. 766 - 766
Published: May 26, 2023
In
a
mutually
beneficial
connection
with
its
host,
the
gut
microbiota
affects
host's
nutrition,
immunity,
and
metabolism.
An
increasing
number
of
studies
have
shown
links
between
certain
types
disease
dysbiosis
or
specific
microorganisms.
Fecal
transplantation
(FMT)
is
strongly
advised
for
treatment
recurrent
resistant
Clostridium
difficile
infection
(CDI)
due
to
outstanding
clinical
effectiveness
against
CDI.
The
therapeutic
potential
FMT
other
disorders,
particularly
inflammatory
bowel
diseases
malignancies,
currently
gaining
more
attention.
We
summarized
most
recent
preclinical
evidence
show
promise
in
management
cancer
as
well
complications
related
after
reviewing
research
on
relationship
cancer.
Medicine,
Journal Year:
2024,
Volume and Issue:
103(2), P. e36957 - e36957
Published: Jan. 12, 2024
Gastrointestinal
(GI)
cancers
pose
a
significant
challenge
due
to
high
prevalence
and
mortality.
While
advancements
in
detection
conventional
treatments
have
been
made,
prognosis
often
remains
poor,
particularly
for
advanced-stage
cancers.
Immunotherapy
has
emerged
as
transformative
approach,
leveraging
the
body
immune
system
against
cancer,
including
checkpoint
inhibitors
(ICIs),
cancer
vaccines,
adoptive
cell
transfer.
These
modalities
shown
promise,
achieving
sustained
responses
improved
survival
some
patients.
However,
their
efficacy
GI
is
less
pronounced,
hindered
by
drug
resistance
mechanisms
that
are
either
intrinsic
or
acquired
over
time.
This
review
examines
latest
understanding
of
immunotherapy
cancers,
focusing
on
ICIs,
transfer,
along
with
associated
outcomes
limitations.
It
delves
into
behind
resistance,
alterations
checkpoints,
immunosuppressive
tumor
microenvironment,
genetic/epigenetic
changes.
The
role
gut
microbiome
also
considered
an
emerging
factor
resistance.
To
combat
strategies
such
enhancing
response,
targeting
modulating
explored.
underscores
potential
ferroptosis
induction
novel
approach.
Looking
forward,
it
highlights
need
personalized
immunotherapies,
influence
microbiome,
further
exploration
overcoming
challenges
persist,
continuous
evolution
research
promises
innovative
could
significantly
improve
patient
outcomes.
Cancer Letters,
Journal Year:
2023,
Volume and Issue:
568, P. 216286 - 216286
Published: June 23, 2023
Pancreatic
cancer
(PC)
is
a
deadly
with
high
mortality
rate.
The
unique
characteristics
of
PC,
including
desmoplasia
and
immunosuppression,
have
made
it
difficult
to
develop
effective
treatment
strategies.
stellate
cells
(PSCs)
play
crucial
role
in
the
progression
disease
by
interacting
cells.
One
key
mediators
PSC
-
cell
interactions
hepatocyte
growth
factor
(HGF)/c-MET
pathway.
Using
an
immunocompetent
vivo
model
PC
as
well
vitro
experiments,
this
study
has
shown
that
combined
approach
using
HGF/c-MET
inhibitors
target
stromal-tumour
chemotherapy
(gemcitabine)
effectively
decreases
tumour
volume,
EMT,
stemness,
importantly,
eliminates
metastasis.
Notably,
inhibition
TGF-β
secretion
cells,
resulting
increase
cytotoxic
T-cell
infiltration,
thus
contributing
death
tumours.
+
was
also
found
normalise
gut
microbiome
improve
microbial
diversity.
These
findings
provide
strong
platform
for
assessment
triple
therapy
(HGF/c-MET
chemotherapy)
clinical
setting.
